Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free NXGLW Stock Alerts

NEXGEL (NXGLW) Competitors

NEXGEL logo
$0.01 +0.00 (+12.30%)
As of 10/2/2026 10:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

NXGLW vs. LUCYW, WOK, MDLN, ALC, and WST

Should you buy NEXGEL stock or one of its competitors? NEXGEL's main competitors and comparable companies include Innovative Eyewear (LUCYW), WORK Medical Technology Group (WOK), Medline (MDLN), Alcon (ALC), and West Pharmaceutical Services (WST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does NEXGEL compare to Innovative Eyewear?

NEXGEL (NASDAQ:NXGLW) and Innovative Eyewear (NASDAQ:LUCYW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
Innovative Eyewear$3.41MN/AN/AN/AN/A

In the previous week, NEXGEL's average media sentiment score of 0.00 equaled Innovative Eyewear'saverage media sentiment score.

Company Overall Sentiment
NEXGEL Neutral
Innovative Eyewear Neutral

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
Innovative Eyewear N/A N/A N/A

Summary

NEXGEL beats Innovative Eyewear on 1 of the 1 factors compared between the two stocks.

How does NEXGEL compare to WORK Medical Technology Group?

NEXGEL (NASDAQ:NXGLW) and WORK Medical Technology Group (NASDAQ:WOK) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
WORK Medical Technology Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, NEXGEL's average media sentiment score of 0.00 equaled WORK Medical Technology Group'saverage media sentiment score.

Company Overall Sentiment
NEXGEL Neutral
WORK Medical Technology Group Neutral

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
WORK Medical Technology Group N/A N/A N/A

NEXGEL has higher revenue and earnings than WORK Medical Technology Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
WORK Medical Technology Group$9.81MN/A-$1.07MN/AN/A

Summary

NEXGEL and WORK Medical Technology Group tied by winning 1 of the 2 factors compared between the two stocks.

How does NEXGEL compare to Medline?

NEXGEL (NASDAQ:NXGLW) and Medline (NASDAQ:MDLN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, Medline had 13 more articles in the media than NEXGEL. MarketBeat recorded 13 mentions for Medline and 0 mentions for NEXGEL. Medline's average media sentiment score of 0.04 beat NEXGEL's score of 0.00 indicating that Medline is being referred to more favorably in the news media.

Company Overall Sentiment
NEXGEL Neutral
Medline Neutral

Medline has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
Medline$28.43B1.65$1.16B$0.7945.08

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
Medline N/A N/A N/A

Medline has a consensus target price of $46.88, suggesting a potential upside of 31.66%. Given Medline's stronger consensus rating and higher probable upside, analysts plainly believe Medline is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Medline
1 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.83

Summary

Medline beats NEXGEL on 7 of the 7 factors compared between the two stocks.

How does NEXGEL compare to Alcon?

Alcon (NYSE:ALC) and NEXGEL (NASDAQ:NXGLW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Alcon currently has a consensus price target of $84.97, indicating a potential upside of 33.30%. Given Alcon's stronger consensus rating and higher possible upside, equities analysts plainly believe Alcon is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alcon
1 Sell rating(s)
6 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.63
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

53.9% of Alcon shares are held by institutional investors. 1.5% of Alcon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Alcon had 5 more articles in the media than NEXGEL. MarketBeat recorded 5 mentions for Alcon and 0 mentions for NEXGEL. Alcon's average media sentiment score of 0.19 beat NEXGEL's score of 0.00 indicating that Alcon is being referred to more favorably in the media.

Company Overall Sentiment
Alcon Neutral
NEXGEL Neutral

Alcon has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alcon$10.40B3.03$980M$1.3148.66
NEXGEL$12.07MN/AN/AN/AN/A

Alcon has a net margin of 5.92% compared to NEXGEL's net margin of 0.00%. Alcon's return on equity of 7.29% beat NEXGEL's return on equity.

Company Net Margins Return on Equity Return on Assets
Alcon5.92% 7.29% 5.09%
NEXGEL N/A N/A N/A

Summary

Alcon beats NEXGEL on 12 of the 12 factors compared between the two stocks.

How does NEXGEL compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and NEXGEL (NASDAQ:NXGLW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, West Pharmaceutical Services had 1 more articles in the media than NEXGEL. MarketBeat recorded 1 mentions for West Pharmaceutical Services and 0 mentions for NEXGEL. West Pharmaceutical Services' average media sentiment score of 0.37 beat NEXGEL's score of 0.00 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Overall Sentiment
West Pharmaceutical Services Neutral
NEXGEL Neutral

West Pharmaceutical Services has a net margin of 16.98% compared to NEXGEL's net margin of 0.00%. West Pharmaceutical Services' return on equity of 20.11% beat NEXGEL's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.98% 20.11% 14.83%
NEXGEL N/A N/A N/A

West Pharmaceutical Services currently has a consensus target price of $382.00, indicating a potential upside of 4.50%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, equities research analysts plainly believe West Pharmaceutical Services is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.86
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

West Pharmaceutical Services has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B8.37$493.70M$7.8146.81
NEXGEL$12.07MN/AN/AN/AN/A

Summary

West Pharmaceutical Services beats NEXGEL on 11 of the 11 factors compared between the two stocks.

Get NEXGEL News Delivered to You Automatically

Sign up to receive the latest news and ratings for NXGLW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXGLW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NXGLW vs. The Competition

Export
MetricNEXGELHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$5.48B$7.15B$13.28B
Dividend YieldN/A1.81%2.54%17.33%
P/E RatioN/A25.42274.7126.04
Price / SalesN/A67.70656.46105.16
Price / CashN/A32.2778.8752.62
Price / BookN/A5.7310.936.31
Net IncomeN/A$152.68M$3.51B$362.16M
7 Day PerformanceN/A-1.71%-2.00%-1.66%
1 Month PerformanceN/A-4.87%-6.19%-4.68%
1 Year PerformanceN/A1.30%8.03%1.57%

NEXGEL Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NXGLW
NEXGEL
N/A$0.01
+12.3%		N/A-95.5%$0.00$12.07MN/A19
LUCYW
Innovative Eyewear
N/A$0.04
-0.6%		N/A-58.2%$0.00$3.41MN/A9
WOK
WORK Medical Technology Group
N/A$1.86
-0.1%		N/A-100.0%$0.00$10.72MN/A226
MDLN
Medline
2.9507 of 5 stars		$34.74
+1.3%		$47.42
+36.5%		N/A$45.56B$28.43B43.8645,000
ALC
Alcon
3.5679 of 5 stars		$64.46
-1.4%		$84.97
+31.8%		-17.6%$31.86B$10.86B49.1725,942

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NXGLW) was last updated on 10/4/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
WATCH THIS BEFORE DECEMBER 8th!!
James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...
Paradigm Press | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
"How Much Can I Actually Spend Each Year With $2.5M Saved?"
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel